Abstract:To improve arrhythmogenic cardiomyopathy (ACM) patient care four pillars of ACM research are necessary. The first pillar to improve ACM is cohort studies in which the genotype‐specific natural history of disease is described, and subsequently genotype‐specific risk calculators can be developed, such as the DSP and PLN risk calculators. The second pillar is the basic and translational studies in which cellular pathways are described and potential genotype‐specific drug targets to slow progression or lower the risk of VA identified, such as flecainide in PKP2‐associated ARVC patients. Third, preclinical gene studies can improve ACM patient care to determine which vector has the optimal effect in which specific gene for gene therapy. The efficacy of gene therapy can subsequently be tested to hopefully improve or even cure ACM in clinical trials. Arrhythmogenic cardiomyopathy (ACM) is a genetically heterogeneous inherited cardiomyopathy with an estimated prevalence of 1:5000–10 000 that predisposes patients to life‐threatening ventricular arrhythmias (VA) and sudden cardiac death (SCD). ACM diagnostic criteria and risk prediction models, particularly for arrhythmogenic right ventricular cardiomyopathy (ARVC), the most common form of ACM, are typically genotype‐agnostic, but numerous studies have established clinically meaningful genotype‐phenotype associations. Early signs of ACM onset differ by genotype indicating the need for genotype‐specific diagnostic criteria and family screening paradigms. Likewise, risk factors for SCD vary by genetic subtype, indicating that genotype‐specific guidelines for management are also warranted. Of particular importance, genotype‐specific therapeutic approaches are being developed. Results from a randomized controlled trial for flecainide use in ARVC patients are currently pending. Research in a plakophilin‐2‐deficient mouse model suggests this antiarrhythmic drug may be particularly useful for patients with likely pathogenic or pathogenic (LP/P) PKP2 variants. Additionally, the first gene therapy clinical trials in ARVC patients harboring LP/P PKP2 variants are currently underway. This review aims to provide clinicians caring for ACM patients with an up‐to‐date overview of the current literature in genotype‐specific natural history of disease and management of ACM patients and describe scientific advances that have led to upcoming clinical trials.

Disputation on the Power and Efficacy of Phenotypical Classification in Arrhythmogenic Cardiomyopathy: Time for a Reformation?!

Definition, Classification and Arrhythmic Risk Stratification

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

Contemporary diagnostic approach to arrhythmogenic cardiomyopathy: The three-step work-up

The "Padua classification" of cardiomyopathies: Combining pathobiological basis and morpho-functional remodeling

Redefining genotype-phenotype correlation among patients with arrhythmogenic cardiomyopathy: a CMR cohort study

Diagnosis and management of arrhythmogenic cardiomyopathy: a case report

Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy

The 2023 European Task Force Criteria for Diagnosis of Arrhythmogenic Cardiomyopathy: Historical Background and Review of Main Changes

Basic and translational mechanisms in inflammatory arrhythmogenic cardiomyopathy

A Novel Genotype-Based Clinicopathology Classification of Arrhythmogenic Cardiomyopathy Provides Novel Insights into Disease Progression.

Arrhythmogenic Cardiomyopathy: Towards Genotype Based Diagnoses and Management

[Diagnosis of arrhythmogenic cardiomyopathy: 20 years of progress and innovation]

Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report

Atrial fibrillation and atrial cardiomyopathies

Multimodality imaging in arrhythmogenic cardiomyopathy - From diagnosis to management

Animal Models and Molecular Pathogenesis of Arrhythmogenic Cardiomyopathy Associated with Pathogenic Variants in Intercalated Disc Genes

Cardiovascular Magnetic Resonance in Cardiomyopathy

Evolving spectrum of arrhythmogenic cardiomyopathy: Implications for Sports Cardiology

Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences

Role of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy